NCT Number: NCT02603705
Safety and Tolerability of Egalet-002 in Patients With Moderate-to-Severe Chronic Noncancer Pain
The purpose of this study is to evaluate the safety and tolerability of Egalet-002 in opioid-experienced patients with moderate-to-severe chronic noncancer pain.
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
Site 334, Huntsville, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Is a man or woman between 18 and 75 years of age.
- Has a clinical history of moderate-to-severe chronic noncancer pain ≥6 months.
- Has required opioid therapy for at least 14 days prior to Screening at a dose between 20 mg and 160 mg (inclusive) oxycodone/day (or opioid equivalent), and will, in the opinion of the investigator, continue to require opioid therapy (between 20 mg and 240 mg oxycodone/day, inclusive) for management of moderate-to-severe pain for the duration of the study.
- Has pain either not adequately controlled on current opioid regimen, requires a change of opioid due to tolerability of current opioid regimen or in the opinion of the investigator, would benefit from changing opioid for another reason.
- Has stable health, as determined by the investigator.
- If female, the patient is currently not pregnant, not breast-feeding, nor attempting to become pregnant (for 30 days before screening through the duration of the study), or is of non-childbearing potential.
- Other Criteria Apply
Exclusion criteria
- Has cancer-related pain.
- Is receiving >240 mg oxycodone daily (or opioid equivalent) within 30 days before Screening.
- Has a history of attempted suicide.
- Has used a spinal infusion pump within 6 months before Screening.
- Has clinically unstable cardiac disease (including atrial fibrillation, symptomatic bradycardia, unstable congestive heart failure, or active myocardial ischemia) and/or respiratory disease (including chronic obstructive pulmonary disease or sleep apnea).
- Has positive urine toxicity screen for drugs of abuse (with the exception of prescribed medications).
- Has positive result for tetrahydrocannabinol (even if legally prescribed).
- Has current (or history of within the last 12 months) drug dependence or substance abuse disorder according to Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, Text Revision criteria (excluding nicotine).
- Other Criteria Apply
Treatment and study plan
Primary outcomes
-
Incidence of TEAEs during the Open-label Treatment Period, including those leading to treatment withdrawal, and/or abnormal physical examination findings, vital signs measurements, ECGs, and clinical laboratory test results, related to treatment
Time frame: 1 year
Secondary outcomes
-
Findings of the Brief Pain Inventory-Short Form (BPI-SF) during the Open-label Treatment Period
Time frame: 1 year
Sponsors and collaborators
Lead sponsor
Egalet Ltd
Industry
Registry information
Official study title
An Open-label Phase 3 Trial to Evaluate the Safety and Tolerability of Egalet ADER Oxycodone Tablet, Egalet-002, in Patients With Moderate-to-Severe Chronic Noncancer Pain
Important dates
- Study start
- 2016
- Primary completion
- 2017
- Study completion
- 2017
- First posted
- Nov 13, 2015
- Registry last updated
- Mar 5, 2018
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Central Pain Mechanisms and Clinical and Psychological Factors Associated With Pain Interference in Daily Life in Adults With Hemophilia and Hemophilic Arthropathy
NCT07516730
Anxiety Disorders, Blood Coagulation Disorders
Oviedo, Principality of Asturias, Spain
View Trial DetailsArthroscopic Infrapatellar Fat Pad Release and Mesenchymal Stem Cell Mobilization
NCT07736716
Chronic Pain, Knee Acute and Chronic Pain
Ankara, Turkey (Türkiye)
View Trial DetailsImproving Communication About Pain and Opioids
NCT03629197
Chronic Pain, Communication Research
Sacramento, California, United States
View Trial DetailsThe Effect of Physiotherapy Integrated With Yoga and Mindfulness on Individuals With Fibromyalgia
NCT07145788
Agnosia, Chronic Pain
Stuttgart, Auerbachstraße 112, Germany
View Trial Details